Bioblast Pharma (ORPN) Competitors

Bioblast Pharma has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Bioblast Pharma's return on equity of 0.00% beat Evofem Biosciences' return on equity.

4.5% of Bioblast Pharma shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Evofem Biosciences has higher revenue and earnings than Bioblast Pharma.

Bioblast Pharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.32, meaning that its stock price is 232% less volatile than the S&P 500.

In the previous week, Evofem Biosciences had 1 more articles in the media than Bioblast Pharma. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Bioblast Pharma. Evofem Biosciences' average media sentiment score of 1.34 beat Bioblast Pharma's score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media.

4.5% of Bioblast Pharma shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bioblast Pharma has higher earnings, but lower revenue than Graybug Vision.

Bioblast Pharma's return on equity of 0.00% beat Graybug Vision's return on equity.

Bioblast Pharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

In the previous week, Graybug Vision's average media sentiment score of 0.84 beat Bioblast Pharma's score of 0.00 indicating that Graybug Vision is being referred to more favorably in the news media.

In the previous week, Bioblast Pharma's average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Bioblast Pharma has higher earnings, but lower revenue than Athersys.

Bioblast Pharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, suggesting that its stock price is 190% less volatile than the S&P 500.

4.5% of Bioblast Pharma shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Bioblast Pharma's average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Bioblast Pharma has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.

4.5% of Bioblast Pharma shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bioblast Pharma's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.